The Infertility Market Size was valued at USD 1.6 billion in 2022 and is projected to grow from USD 1.804 Billion in 2023 to USD 4.72 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.8% during the forecast period (2023 - 2032). Effective infertility treatments are made possible by fertility services, which also provide alternatives. The services aid in resolving infertility concerns in couples dealing with parenting issues brought on by biological issues, the LGBT community, and single parents. Surrogacy, in vitro fertilization (IVF), artificial insemination, and others are the most often used methods. A lack of semen or eggs hampers the pregnancy. The issues above are driving the infertility market's explosive expansion, thus driving the market growth of the Infertility. These are just a few of the market drivers that are driving the market.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
At around $1.1 billion valuation, private equity firm BPEA EQT acquired a 60% stake in Indira IVF Hospital Pvt. Ltd., the largest network of reproductive clinics in India, from TA Associates and Founders in February 2024. Indira IVF is embarking on its next phase of sustainable growth through partnering with BPEA EQT. Indira IVF has grown from just one clinic to a national network with outlets situated throughout twenty-four Indian states. These institutions complete about forty thousand cycles yearly and offer assisted reproductive technology in India.
In February 2024, global biopharmaceuticals company Lupin Limited announced the introduction of Ganirelix Acetate Injection after securing clearance from the United States Food and Drug Administration (U.S FDA); it is indicated for preventing ovulation induction (luteinizing hormone increase) during controlled ovarian hyperstimulation.
Cercle—a healthcare sector-focused AI technology company that offers robust data analytics–made its debut in the industry in November 2023. Its CercleTM Biomedical Graph is a unique technological platform that links and leverages billions of confidential biomedical and genetic data points harvested from around the world through research labs and medical clinics.
Indira IVF Hospital Pvt. Ltd., India’s largest network of reproductive clinics, was acquired by BPEA EQT for an undisclosed amount in July 2023.
For example, as of April 2022, Japan’s publicly funded health care will pay for fertility treatments, thereby making them cheaper by about 70% than they are at present to patients so as to be more accessible. This will boost market development because there will also be numerous medications available that can treat infertility cases.
BPEA EQT acquired Indira IVF Hospital Pvt. Ltd., India’s biggest network of reproductive clinics, for $1.1 billion from TA Associates and the founders of the company. By partnering with BPEA EQT Indira IVF is entering into new pages of sustainable growth. The organization has grown from just one facility to over a hundred national branches across twenty Indian states with about forty thousand cycles per year and ART services in India being provided there annually.
Fertility rate is declining among both men and women owing to the sedentary lifestyle driving the market growth
The prevalence of infertility in both the male and female populations and the rate of infertility disorders are the two main factors propelling the growth of the market for fertility services. Also, the market is anticipated to develop due to the increase in fertility services-related product launches, approvals, and technical advancements. The market will increase during the forecast period due to the rising use of in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI) technology, which has a high success rate in treating infertility as the rising public demand for fertility services.
The propensity for delayed pregnancy has gradually increased around the world. Older women (those over 40) generate eggs but are still waiting for male spermatozoa to fertilize them. As a result, genetic disorders in the egg may be dangerous. In older persons, fewer good eggs are produced. Typically, older women only lay a small number of poor-quality eggs. These factors could put the egg at risk for genetic abnormalities. The CDC forecasted a fall in birth rates among women aged 35 to 39 in 2020, assisting the market for fertility therapies in expanding. Thus, this factor is driving the market CAGR.
According to World Health Organization (WHO) calculations, PCOS affects more than 116 million women ly (3.4%). In addition, the Lancet article states that in 2020, it is anticipated that there will be 24 million PCOS-affected women in China. As a result, this factor may increase the demand for fertility treatments among females with the polycystic ovarian syndrome, which is expected to boost the market for these services. Thus, it is anticipated that this aspect will accelerate Infertility market revenue globally.
The market segments of Infertility, based on sex includes males, females, and unexplained. The closure devices segment held the majority share in 2022 in the Infertility market data. Due to the high female infertility rate worldwide brought on by obesity, an unhealthy lifestyle, and conditions like polycystic ovary syndrome, the female infertility treatment segment commands the largest revenue market share in the infertility. This trend is likely to persist during the forecast period (PCOS).
The Infertility market segmentation, based on diagnosis, includes men diagnostic tests, women diagnostic tests, and general diagnostic test. The men diagnostic tests segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Due to technological improvements, computer-assisted semen analysis is anticipated to experience a significant increase in the years to come. The most popular diagnostic test is a semen analysis, which can be carried out using microscopic examination methods. For instance, Sandstone Diagnostics launched Trak Volume Cup in April 2018 after receiving FDA certification from the United States. This gadget enables men to measure semen volume and identify hypothermia at home, hence contributing in the market growth of the Infertility.
Figure 2 Infertility Market, by Diagnosis, 2022 & 2030 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The market segmentation of Infertility, based on drugs includes clomiphene citrate, letrozole, serophene, hormone treatment, and others. The hormone treatment segment held the majority share in 2022 in the Infertility market data. This can be ascribed to the expensive nature of the products and the higher efficacy's effect on increased consumption. The gonadotropins Gonal-F, Follitism, Menopur, and Bravelle are some of the most frequently prescribed for treating infertility in patients. Hence, gonadotropins' high efficacy may draw in a new target market and increase the source of income.
The market segmentation of Infertility, based on technology, includes assisted reproductive technology, intrauterine insemination, and surgery. The assisted reproductive technology segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Several idiopathic reasons, including sperm autoantibodies, viral orchitis, epididymal dysfunction, accessory gland infection, chemotherapy, heat, trauma, and other idiopathic factors, primarily cause male infertility. ARTs are used to treat these issues. One of the main elements influencing segment growth is the high cost of care and the necessity of multiple additional therapeutic cycles. The main reasons expected to propel the ART segment over the forecast period are rising healthcare spending in emerging nations, increased awareness of male infertility, and rising adoption in the middle- and low-income nations., hence contributing in the market growth of the Infertility.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Infertility market accounted for USD 0.732 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Due to the introduction and quick use of numerous infertility medications. Rising infertility research activity in the area is anticipated to create additional job possibilities. For instance, Ferring B.V. and Igenomix signed a four-year research agreement in June 2020 to collaborate on developing novel therapeutic products for the care of patients with disorders associated with pregnancy. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.
Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 INFERTILITY MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Infertility market accounts for the second-largest market share. This is ascribed to the availability of modern, well-equipped fertility clinics, the increased use of more expensive treatments, improved access to diagnosis and care, and high levels of knowledge. Furthermore, the regional market's growth is greatly influenced by healthcare spending and the availability of well-established healthcare infrastructure. Moreover, UK market of Infertility held the largest market share, and the Germany market of Infertility was the fastest growing market in the region.
Asia Pacific Infertility Market is expected to grow at the fastest CAGR from 2022 to 2030 India, China, and Singapore are among the emerging nations with rapid economic expansion. The growth of male infertility and improvements in medical diagnostics is driving the Asian market. The incidence rate of male infertility has increased due to the aging population's growth and the rise in disorders linked to lifestyle. Further, the China market of Infertility held the largest market share, and the India market of Infertility was the fastest-growing market in the region.
Infertility Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of Infertility grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Infertility industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Infertility industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Infertility industry has provided medicine with some of the most significant benefits. The market of Infertility major player such Olympus Corporation, The Cooper Companies Inc., Virtus Health, CooperSurgical, Inc., Vitro life CARE Fertility.
Aytu BioScience, a developing specialty pharmaceutical firm, is focused on commercializing cutting-edge pharmaceuticals that effectively meet pressing patient needs (NASDAQ AYTU). The MiOXSYS system, which assists in evaluating semen quality, was approved by the Australian Therapeutic Goods Administration (TGA) in November 2017 by Aytu BioScience.
The Merck Group of Darmstadt, Germany, manufactures and markets its products through Merck Specialities Private Limited. It provides top-notch chemical and pharmaceutical products to the Indian market. Merck KGaA fully owns this 2005-established entity. Merck Specialty Pvt ltd introduced Pergoveris Pen to improve infertility therapy in India in August 2021.
Key Companies in the market of Infertility includes
Infertility Industry Developments
September 2022 Twelve medications, including Letrozole from Novartis AG and Cabaser from Pfizer, were approved for further infertility treatment by the Ministry of Health, Labor, and Welfare (MHLW). This label expansion approval was predicted to increase the demand for innovative medications in the Asia Pacific.
February 2022 To treat patients' pregnancy-related difficulties, Mankind Pharma created and introduced a generic version of Dydrogestrone pills in India. This medication served as a replacement for Abbott Duphaston pills. This introduction was predicted to propel the demand for infertility treatments.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.6 billion |
| Market Size 2023 | USD 1.804 billion |
| Market Size 2032 | USD 4.72 billion |
| Compound Annual Growth Rate (CAGR) | Â 12.8% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Sex, Diagnosis, Drugs, Technology and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Olympus Corporation, The Cooper Companies Inc., Virtus Health, CooperSurgical, Inc., Vitro life CARE Fertility |
| Key Market Opportunities | Single parents and same-sex parents |
| Key Market Dynamics | Fertility rate is declining among both men and women owing to the sedentary lifestyle |
Infertility Market Highlights:
Frequently Asked Questions (FAQ) :
The Infertility market size was valued at USD 1.6 Billion in 2022.
The market is projected to grow at a CAGR of 12.8% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in Olympus Corporation, The Cooper Companies Inc., Virtus Health, CooperSurgical, Inc., Vitro life CARE Fertility.
The female category dominated the market in 2022.
The hospital had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
